About: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Creator	Raoult, Didier Colson, Philippe Rolain, Jean-Marc Gautret, Philippe Brouqui, Philippe Parola, Philippe Lagier, Jean-Christophe Doudier, Barbara Courjon, Johan Didier, Raoult Hoang, Van Mailhe, Morgane Scola, Bernard Chabrière, Eric Dupont, Tissot Giordanengo, Valérie Honoré, Stéphane Meddeb, Line Vieira, Vera Didier,
Source	Elsevier; Medline; PMC
abstract	Abstract Background Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads. Patients and methods French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16th, to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point. Results Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination. Conclusion Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.
has issue date	2020-03-20(xsd:dateTime)
bibo:doi	10.1016/j.ijantimicag.2020.105949
bibo:pmid	32205204
has license	els-covid
sha1sum (hex)	73243d95149d9f2260f3c852599d7d39f4cc8ccc
schema:url	https://doi.org/10.1016/j.ijantimicag.2020.105949
resource representing a document's title	Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
has PubMed Central identifier	PMC7102549
has PubMed identifier	32205204
schema:publication	Int J Antimicrob Agents
resource representing a document's body	covid:73243d95149d9f2260f3c852599d7d39f4cc8ccc#body_text
is schema:about of	named entity 'EVALUATE' named entity 'ROLE' covid:arg/73243d95149d9f2260f3c852599d7d39f4cc8ccc named entity 'VIRAL' named entity 'PATIENTS' named entity 'OPEN' named entity 'TREATMENT' named entity 'LABEL' named entity 'RESULTS' named entity 'AZITHROMYCIN' named entity 'NON-RANDOMIZED CLINICAL TRIAL' named entity 'HYDROXYCHLOROQUINE' named entity 'FOUND' named entity 'COVID-19' named entity 'HAVE' named entity 'CHLOROQUINE' named entity 'HYDROXYCHLOROQUINE' named entity 'REPORTED' named entity 'RESPIRATORY' named entity 'CHINESE' named entity 'EFFICIENT' named entity 'SARS-COV-2' named entity 'hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'Chloroquine' named entity 'SARS-CoV-2' named entity 'synergistic effect' named entity 'COVID' named entity 'control patients' named entity 'cytopathogenic effect' named entity 'mortality rate' named entity 'COVID' named entity 'Hydroxychloroquine' named entity 'administrated' named entity 'WHO' named entity 'nasopharyngeal' named entity 'rhinitis' named entity 'long-term' named entity 'Marseille' named entity 'contraindication' named entity 'clinical examination' named entity 'Marseille' named entity 'hydroxychloroquine' named entity 'G6PD deficiency' named entity 'spread of COVID-19' named entity 'supernatant' named entity 'hydroxychloroquine' named entity 'pneumonia' named entity 'hydroxychloroquine' named entity 'Tropheryma whipplei' named entity 'COVID' named entity 'virus' named entity 'sampling' named entity 'serum' named entity 'asymptomatic carriers' named entity 'clinical outcome' named entity 'virus' named entity 'control group' named entity 'nasopharyngeal' named entity 'hydroxychloroquine' named entity 'pharyngitis' named entity 'healthcare workers'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software